Crossmark

Reply to comments on: “Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn’s disease—A prospective nationwide multicenter cohort study”

Crossref DOI link: https://doi.org/10.1007/s00508-024-02363-z

Published Online: 2024-04-23

Published Print: 2024-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Riss, Stefan

Dawoud, Christopher https://orcid.org/0000-0003-1432-2804
License Information

Text and Data Mining valid from 2024-04-23

Version of Record valid from 2024-04-23
More Information

Article History

Received: 28 March 2024

Accepted: 30 March 2024

First Online: 23 April 2024

Conflict of interest

: C. Dawoud had honoraria for invited presentations during satellite symposia from Takeda. Neither funding nor financial support was administered for the current study. S. Riss had honoraria from Takeda for invited presentations during advisory board meetings and satellite symposia. Neither funding nor financial support was administered for the current study.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below